CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
Active, not recruiting · NCT06231368 · Registry updated 2025-05-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Active, not recruiting | Phase 1 | 2025-05-16 | NCT06231368 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 285 |
| Juventas Cell Therapy Ltd. | 16 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Regenerative Medicine Center | Tianjin | China | 7 |